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Background
Macrophage activation syndrome (MAS) is a rare compli-
cation of childhood with rheumatic disease. This syn-
drome has been reported in association with many
rheumatic diseases, especially systemic juvenile rheuma-
toid arthritis (SoJIA). The aim of this study was evaluation
the rate, symptoms and outcome of MAS during 10 years.
Methods
Retrospective review of cases of MAS from the charts of
120 patients with juvenile rheumatoid arthritis and sys-
temic lupus erythematosus (SLE), were reviewed collected
data base of 5 children with MAS from 1998 to 2007, in
Children's Medical Center, In Tehran University.
Results
Totally 120 patients evaluated in this study including 108
JIA and 12 SLE. Five patients (4 girls and 1 boy) were con-
sidered to have evidence of MAS (incidence rate 4.2%).
This rate for all JIA patients was 3.7% and for SoJIA, SLE
and juvenile idiopaticarthritis (JIA) and polyarticular RF
negative JIA was 8.2%, 16.7% and 2.8%, respectively.
Mean age of MAS onset was 4.9 years, and duration of
rheumatologic disease prior to MAS, 22 months. Four
cases (80%) had abnormal liver function during the dis-
ease course, and coagulopathy. Bone marrow examina-
tion supported the diagnosis with definite
haemophagocytosis in four cases (80%). The mortality
rate was 40%.
Conclusion
Incidence of MAS in our JIA patients was about other stud-
ies, but the mortality rate was higher than other reports.
Although MAS is a rare complication, because it is poten-
tially fatal it must be considered in each childhood rheu-
matic disorders with suddenly changes in general
condition and decrease peripheral cells.
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